IL2RA and hemophagocytic syndrome: HLH can be life-threatening if not treated properly, with a mortality rate ranging from 20-70% so treatment response should be monitored closely [14]. Reduction in fever, improvements in liver/kidney function and coagulation profile, improvement in myelosuppression, and down-trending ferritin and IL-2R can be good clinical indicators [15].